Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical
Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUOLatest Information Update: 16 Aug 2024
At a glance
- Originator WuXi Biologics
- Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer; Hodgkin's disease
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
- Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
- No development reported Cancer; Glioblastoma
- Discontinued Prostate cancer
Most Recent Events
- 08 Aug 2024 Arcus Biosciences completes enrolment from its Phase-III clinical trials in Gastrointestinal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Lithuania, Spain, Hungary, USA (IV) (NCT05568095)
- 29 Jul 2024 Compugen plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA in the fourth quarter of 2024 (Parenteral),
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)